China has recently issued new rules allowing the submission of supplemental testing data on medical and pharmaceutical inventions during substantive patent examinations and invalidity proceedings under certain conditions. Previously, China rejected all such data. This webinar explored the new Chinese rules, best practices for submitting supplemental data based on the long history of this practice in the United States, and how this development improves patent protection for medical and pharmaceutical inventions in China.
- Jing Zhang, Partner, Mayer Brown
- Gary M. Hnath, Partner, Mayer Brown
- Scott A. McMurry, PhD, Associate, Mayer Brown
- Derek Lu, Partner, Zhilin Law Firm
CLE is not available when viewing a recording of this program. In order to receive credit you must have attended the live webinar program.